Burden of skeletal-related events in prostate cancer: unmet need in pain improvement

被引:47
作者
Broder, M. S. [1 ]
Gutierrez, B. [2 ]
Cherepanov, D. [1 ]
Linhares, Y. [3 ]
机构
[1] Partnership Hlth Analyt Res LLC, Beverly Hills, CA 90212 USA
[2] Otsuka Amer Pharmaceut Inc, Princeton, NJ 08540 USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
关键词
Prostatic neoplasms; Bone neoplasms; Fractures; Bone; Spinal cord compression; Radiotherapy; Pain; prostate cancer; metastatic bone disease; bone metastases; skeletal-related events; QUALITY-OF-LIFE; METASTATIC BONE-DISEASE; SPINAL-CORD COMPRESSION; RANDOMIZED PHASE-II; ZOLEDRONIC ACID; PALLIATIVE TREATMENT; SURVIVAL; TRIAL; RADIOTHERAPY; CARCINOMA;
D O I
10.1007/s00520-014-2437-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Up to 75 % of patients with prostate cancer experience metastatic bone disease, which leads to an increased risk for skeletal-related events (SREs) including pathological bone fracture, spinal cord compression, and hypercalcemia of malignancy. Our objective was to systematically review the literature on the impact of SREs on quality of life (QOL), morbidity, and survival with a primary focus on the impact of SREs on pain in prostate cancer patients. We searched PubMed, limiting to peer-reviewed English-language human studies published in 2000-2010. The search was based on the US Food and Drug Administration and European Medicines Agency definition of an SRE, which includes pathologic fracture, spinal cord compression (SCC), hypercalcemia of malignancy, and radiotherapy or surgery to bone resulting from severe bone pain. A total of 209 articles were screened, of which 173 were excluded, and 36 were included in this review. Patients with SREs had more pain and worse survival compared with no SREs. Pathologic bone fractures worsened QOL and were associated with shorter survival. Radiation therapy of SCC alleviated pain and improved morbidity. SCC was associated with decreases in patient survival. Radiation therapy and surgery to bone improved pain. Specific SREs are associated with worse outcomes, including increased pain, poorer QOL, morbidity, and survival. Treatment of SREs is associated with improved pain, although there remains a need for more effective treatment of SREs in prostate cancer patients.
引用
收藏
页码:237 / 247
页数:11
相关论文
共 54 条
  • [31] Palliation of bone pain in prostate cancer using chemotherapy and strontium-89.: A randomized phase II study
    Nilsson, S
    Strang, P
    Ginman, C
    Zimmermann, R
    Edgren, M
    Nordström, B
    Ryberg, M
    Kälkner, KM
    Westlin, JE
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2005, 29 (04) : 352 - 357
  • [32] Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:: a randomised, multicentre, placebo-controlled phase II study
    Nilsson, Sten
    Franzen, Lars
    Parker, Christopher
    Tyrrell, Christopher
    Blom, Rene
    Tennvall, Jan
    Lennernas, Bo
    Petersson, Ulf
    Johannessen, Dag C.
    Sokal, Michael
    Pigott, Katharine
    Yachnin, Jeffrey
    Garkavij, Michael
    Strang, Peter
    Harmenberg, Johan
    Bolstad, Bjorg
    Bruland, Oyvind S.
    [J]. LANCET ONCOLOGY, 2007, 8 (07) : 587 - 594
  • [33] Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007)
    Norgaard, Mette
    Jensen, Annette Ostergaard
    Jacobsen, Jacob Bonde
    Cetin, Kara
    Fryzek, Jon P.
    Sorensen, Henrik Toft
    [J]. JOURNAL OF UROLOGY, 2010, 184 (01) : 162 - 167
  • [34] What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
    Oudard, Stephane
    Banu, Eugeniu
    Medioni, Jacques
    Scotte, Florian
    Banu, Adela
    Levy, Eric
    Wasserman, Johana
    Kacso, Gabriel
    Andrieu, Jean-Marie
    [J]. BJU INTERNATIONAL, 2009, 103 (12) : 1641 - 1646
  • [35] Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate
    Palmedo, H
    Manka-Waluch, A
    Albers, P
    Schmidt-Wolf, IGH
    Reinhardt, M
    Ezziddin, S
    Joe, A
    Roedel, R
    Fimmers, R
    Knapp, FF
    Guhlke, S
    Biersack, HJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2869 - 2875
  • [36] Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer
    Rades, D
    Stalpers, LJA
    Veninga, T
    Rudat, V
    Schulte, R
    Hoskin, PJ
    [J]. JOURNAL OF UROLOGY, 2006, 175 (02) : 552 - 556
  • [37] Rove KO, 2011, ONCOLOGY-NY, V25, P1362
  • [38] A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Saad, F
    Gleason, DM
    Murray, R
    Tchekmedyian, S
    Venner, P
    Lacombe, L
    Chin, JL
    Vinholes, JJ
    Goas, JA
    Chen, B
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (19): : 1458 - 1468
  • [39] Pathologic fractures correlate with reduced survival in patients with malignant bone disease
    Saad, Fred
    Lipton, Allan
    Cook, Richard
    Chen, Yin-Miao
    Smith, Matthew
    Coleman, Robert
    [J]. CANCER, 2007, 110 (08) : 1860 - 1867
  • [40] Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease:: A randomized phase III trial of the international atomic energy agency (IAEA)
    Salazar, OM
    Sandhu, T
    da Motta, NW
    Escutia, MAP
    Lanzós-Gonzales, E
    Mouelle-Sone, A
    Moscol, A
    Zaharia, M
    Zaman, S
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (03): : 765 - 775